SCHEMBL5459985

SCHEMBL5459985

NC(=O)c1c(NC(=O)NCc2ccccc2)sc2c1CCOC2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.57
FLT3 P36888 4/20 0.52
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
RAB7A P51149 1/20 0.50
EPHB4 P54760 1/20 0.50
PTPRC P08575 1/20 0.49
PTPN2 P17706 1/20 0.49
PTPN1 P18031 1/20 0.49
PTPRB P23467 1/20 0.49
PTPRE P23469 1/20 0.49
USP36 Q9P275 1/20 0.49
ANO1 Q5XXA6 1/20 0.48
CASP3 P42574 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
CXCR2 P25025 1/20 0.46
TNIK Q9UKE5 1/20 0.46
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459377 0.90 CFTR (0.60) CFTRFLT3NPC1RAB9AMEN1
SCHEMBL5456065 0.88 CFTR (0.56) CFTRFLT3NPC1RAB9AMEN1
SCHEMBL5458411 0.87 CFTR (0.55) CFTRFLT3MEN1KMT2AUSP36
SCHEMBL5458021 0.86 CFTR (0.58) CFTRFLT3NPC1RAB9AMEN1
SCHEMBL5450840 0.85 CFTR (0.54) CFTRFLT3NPC1RAB9AMEN1
SCHEMBL5455947 0.84 MEN1 (0.65) CFTRFLT3NPC1RAB9AMEN1
SCHEMBL5453363 0.84 FLT3 (0.71) CFTRFLT3NPC1RAB9AMEN1
SCHEMBL5459795 0.83 KMT2A (0.59) CFTRFLT3NPC1RAB9AMEN1
SCHEMBL5444968 0.83 FLT3 (0.73) CFTRFLT3NPC1RAB9ARAB7A
SCHEMBL5463075 0.82 FLT3 (0.53) FLT3NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885FLT3 3509/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.